Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Alendronic acid
Drug ID BADD_D00066
Description Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].
Indications and Usage For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.
Marketing Status Prescription; Discontinued
ATC Code M05BA04
DrugBank ID DB00630
KEGG ID D07119
MeSH ID D019386
PubChem ID 2088
TTD Drug ID D09KLR
NDC Product Code Not Available
Synonyms Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax
Chemical Information
Molecular Formula C4H13NO7P2
CAS Registry Number 66376-36-1
SMILES C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.0300.000505%Not Available
Skin wound23.03.11.022; 12.01.06.0150.000303%Not Available
Meniscus injury15.07.03.006; 12.04.03.0080.003839%Not Available
Invasive ductal breast carcinoma16.10.01.013; 21.05.01.0210.000707%Not Available
Large intestine benign neoplasm16.05.01.004; 07.20.01.0130.000303%Not Available
Idiopathic orbital inflammation06.04.11.0020.000303%Not Available
Chronic papillomatous dermatitis23.01.04.005; 12.02.16.0020.000303%Not Available
Lumbosacral radiculopathy17.10.03.0050.001313%Not Available
Intracranial mass17.11.01.0170.000202%Not Available
Spinal flattening15.10.04.0110.000303%Not Available
The 49th Page    First    Pre   49    Total 49 Pages